From the discovery to preclinical studies of biopharmaceuticals
Integrated in vivo pharmacological service platform：PD/PK/Toxicology
In Vivo pharmacology research runs through the entire process of drug development, guiding the achievement of key milestones in new drug development, including target validation, leads screening, drug optimization, and the formulation of first clinical protocols.
Genscript ProBio’s in vivo pharmacology R.&D. service platform provides a range of services for various types of drugs such as monoclonal antibodies, bispecific antibodies, ADCs, CGTs, recombinant proteins, and vaccines. These services include in vivo pharmacodynamics evaluation, in vivo pharmacokinetics, toxicology studies, and biological sample analysis. Combining one-stop project management, our platform meets the compliance requirements for new drug applications, enabling faster, better, and more cost-effective.
In vivo efficacy studies
In vivo pharmacokinetic studies
Safety Evaluation (Early stage & GLP)
Bioanalytical detection (customized)
Our platform provides a comprehensive one-stop service, ranging from the establishment of tumor cell lines or disease models to efficacy testing, providing pharmacological animal models primarily focused on anti-tumor effects and disease model efficacy evaluation, with an emphasis on metabolic and autoimmune diseases.
Animal Cell Model：
Disease Animal Model：
PK research based on ELISA, FACS and other detection techniques, we can provide PK studies of various biologics including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), proteins, vaccines, etc., suitable for rodent animals and primates such as cynomolgus monkeys.
Our platform offers early toxicology platforms and collaborating with high-quality CRO companies to conduct formal preclinical toxicology studies.
Bioanalysis platform, utilizing ELISA, FACS, IHC, and Pathology, is applicable for efficacy, pharmacokinetic, and safety evaluation studies of various biologics forms including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), proteins, and vaccines, utilizing rodents, non-human primates such as cynomolgus monkeys, and other primate models.
GenScript ProBio’s in vivo Pharmacology (IVP) Department offers clients an integrated IND project one-stop solution, covering in vivo efficacy, pharmacokinetics, safety evaluation, and more. By leveraging this cooperative model, our clients can benefit from a ready-to-go team of professionals. This seamless integration allows for a smooth connection between project CMC and in vivo pharmacology. As a result, we can expedite the IND submission process, with the capability to complete it within a remarkable 10-month timeframe. Moreover, we ensure compliance with regulatory requirements across multiple countries, meeting the standards set by NMPA, FDA, and EMA.
*Cooperate with high-quality CRO companies, integrate superior resources, and carry out preclinical GLP toxicology studies that meet the declaration requirements.
I agree to receive the latest news, information, promotions, webinars and services, and acknowledge that I can opt out any time.